Surrozen (NASDAQ:SRZN) Major Shareholder Purchases $95,548.70 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc acquired 4,355 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were bought at an average price of $21.94 per share, for a total transaction of $95,548.70. Following the completion of the acquisition, the insider owned 641,685 shares in the company, valued at approximately $14,078,568.90. This trade represents a 0.68% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The stock was bought at an average cost of $21.38 per share, for a total transaction of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc purchased 4,271 shares of Surrozen stock. The shares were bought at an average cost of $21.39 per share, with a total value of $91,356.69.

Surrozen Price Performance

NASDAQ:SRZN traded up $0.98 during trading hours on Tuesday, reaching $23.08. 54,131 shares of the company were exchanged, compared to its average volume of 146,533. The firm has a market cap of $197.80 million, a price-to-earnings ratio of -1.03 and a beta of 0.58. The stock has a 50 day simple moving average of $20.57 and a 200 day simple moving average of $15.04. Surrozen, Inc. has a 52-week low of $5.90 and a 52-week high of $24.94.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. On average, analysts predict that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SRZN has been the topic of a number of research reports. Wall Street Zen upgraded Surrozen to a “sell” rating in a report on Friday, November 28th. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Investors Weigh In On Surrozen

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares in the last quarter. Stonepine Capital Management LLC raised its stake in shares of Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after purchasing an additional 20,247 shares during the period. Stempoint Capital LP raised its stake in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after purchasing an additional 445,713 shares during the period. Armistice Capital LLC acquired a new position in shares of Surrozen during the second quarter worth $536,000. Finally, Braidwell LP purchased a new position in shares of Surrozen in the second quarter valued at $1,252,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.